Dordaviprone under FDA priority review for aggressive glioma type

rarecancernews.com

Factuality

Ownership

Dordaviprone under FDA priority review for aggressive glioma type

The U.S. Food and Drug Administration (FDA) has agreed to a priority review of a Chimerix application seeking accelerated approval of dordaviprone, its oral therapy candidate for people with recurrent, diffuse glioma — a group of brain tumors — positive for the H3 K27M mutation. Recurrent means the cancer has come back after initial treatment, while diffuse means it’s spread from its initial location and has widely infiltrated healthy brain tiss…